This study is testing a new medicine called EPI-7386 for men with prostate cancer that doesn’t respond to hormone lowering treatment. Prostate cancer is a disease where cells in the prostate gland grow out of control. The study has two parts: Part A checks the safety of EPI-7386 alone, and Part B examines its effects when combined with other drugs. Everyone in the study will receive EPI-7386.

Key Points:

• The study involves multiple visits and tests to monitor how EPI-7386 affects you.
• You'll need to meet specific health criteria to join the study, such as having prostate cancer that is resistant to castration (hormone therapy).
• There is a focus on safety, so any new or serious side effects will be closely watched.

Because EPI-7386 is being tested for the first time, researchers are unsure about the best dose and potential side effects. Participants must be 18 or older and have previously tried other treatments that didn’t work. The study will check how EPI-7386 moves through the body and how it affects the cancer and other body substances. Participants should discuss risks and benefits with their doctor before joining.